OncoVista Innovative Therapies, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

April 2024 | 50 pages | ID: OA3B1096362BEN
BAC Reports

Abstracts

OncoVista Innovative Therapies, Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between OncoVista Innovative Therapies, Inc. and its competitors. This provides our Clients with a clear understanding of OncoVista Innovative Therapies, Inc. position in the Pharmaceuticals and Biotechnology Industry.

• The report contains detailed information about OncoVista Innovative Therapies, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• Another part of the report is a SWOT-analysis carried out for OncoVista Innovative Therapies, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
• The OncoVista Innovative Therapies, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
• In the part that describes OncoVista Innovative Therapies, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of OncoVista Innovative Therapies, Inc. business.

About OncoVista Innovative Therapies, Inc.

OncoVista Innovative Therapies, Inc., a biopharmaceutical company, focuses on commercializing diagnostic tests for metastatic tumors, as well as developing targeted anticancer therapies by utilizing tumor-associated biomarkers.

The company has developed diagnostic kits for breast, colon, ovarian, and prostate cancers, and markets diagnostic kits in Europe for the detection of circulating tumor cells (CTCs) in patients with breast and colon cancer.

Product and Product Candidate Pipeline

The company’s portfolio of compounds and technologies under development or planned development include: AdnaGen Oncology Diagnostics; A Liposomal TS Inhibitor; Cordycepin; L-Nucleoside Conjugates; and Novel Tubulin Isotype-Specific Anti-Mitotics.

AdnaGen Diagnostic Products

The company's subsidiary, AdnaGen A.G., markets AdnaGen kits for detection of circulating tumor cells (CTCs) in metastatic colon, metastatic breast cancer, and ovarian patients in Europe.

In September 2008, AdnaGen entered into a distribution and license agreement with Biomarkers LLC (Biomarkers) granting Biomarkers the right to distribute the AdnaGen diagnostic kits in North America. AdnaGen also entered into a distribution and license agreement with Biomarkers granting Biomarkers the right to commercialize the AdnaGen diagnostic kits for research and development purposes only in South America and the Middle East.

Liposomal Thymidylate Synthase (TS) Inhibitor (OVI-237) (solid tumors)

OVI-237 is the company’s advanced clinical stage drug. OVI-237 is a liposome encapsulated formulation of a potent thymidylate synthase inhibitor (TSI) with activity at picomolar concentrations. It was obtained as a result of a worldwide licensing agreement with OSI Pharmaceuticals (Melville, New York). With OVI-237, it has finalized the protocol and selected clinical sites to conduct a phase II study of OVI-237 monotherapy and combination therapy with cisplatin for the treatment of metastatic breast cancer.

Cordycepin (OVI-123) (TdT-Positive Refractory Leukemias)

The company is developing Cordycepin as a treatment option for certain leukemia patients that are either refractory to chemotherapeutics or have experienced a relapse. Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. Cordycepin has been studied in a National Cancer Institute-sponsored phase I clinical trial for treating TdT-positive leukemia patients. It initiated a Phase I/II trial based on the original ADA-sensitive compound.

L-Nucleoside Conjugate (OVI-117)

The company’s L-nucleoside conjugate technology might take advantage of cell membrane changes that differentiate cancerous cells from healthy cells. Drug candidates using L-nucleoside conjugate technology have demonstrated for colorectal, pancreas, melanoma, leukemia, and prostate cancers. OVI-117 has shown anti-tumor activity in animal models of various human cancers (including breast, prostate, and colon) and its target indication would be colorectal cancer. The L-nucleoside conjugate technology was obtained through a right and license to utilize the patents and technologies of Lipitek International, Inc. relating to L-nucleosides and their conjugates.

The company has accumulated in vitro and in vivo data indicating that the L-nucleoside conjugates are effective against various types of cancer. One of its L-nucleoside conjugate candidates, OVI-117, is a conjugate of an L-nucleoside (L-uridine) and the highly toxic compound 5’-fluorodeoxyuridine monophosphate (FdUMP), a thymidylate synthase (TS) inhibitor.

Collaborative Relationships and Partnerships

The company has relationships with the University of Texas Health Science Center at San Antonio (UTHSCSA), the Cancer Therapy and Research Center (CTRC), the Dana-Farber Cancer Institute, MD Anderson Cancer Center, and the San Antonio Cancer Institute (SACI), a cancer research institute.

History

OncoVista Innovative Therapies, Inc. was incorporated in 2004.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. ONCOVISTA INNOVATIVE THERAPIES, INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. ONCOVISTA INNOVATIVE THERAPIES, INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. ONCOVISTA INNOVATIVE THERAPIES, INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. ONCOVISTA INNOVATIVE THERAPIES, INC. FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. ONCOVISTA INNOVATIVE THERAPIES, INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. OncoVista Innovative Therapies, Inc. Direct Competitors
5.2. Comparison of OncoVista Innovative Therapies, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of OncoVista Innovative Therapies, Inc. and Direct Competitors Stock Charts
5.4. OncoVista Innovative Therapies, Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. OncoVista Innovative Therapies, Inc. Industry Position Analysis

6. ONCOVISTA INNOVATIVE THERAPIES, INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. ONCOVISTA INNOVATIVE THERAPIES, INC. EXPERTS REVIEW¹

7.1. Experts Consensus
7.2. Experts Revisions

8. ONCOVISTA INNOVATIVE THERAPIES, INC. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. ONCOVISTA INNOVATIVE THERAPIES, INC. IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. ONCOVISTA INNOVATIVE THERAPIES, INC. PORTER FIVE FORCES ANALYSIS²

12. ONCOVISTA INNOVATIVE THERAPIES, INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

OncoVista Innovative Therapies, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
OncoVista Innovative Therapies, Inc. 1-year Stock Charts
OncoVista Innovative Therapies, Inc. 5-year Stock Charts
OncoVista Innovative Therapies, Inc. vs. Main Indexes 1-year Stock Chart
OncoVista Innovative Therapies, Inc. vs. Direct Competitors 1-year Stock Charts
OncoVista Innovative Therapies, Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

OncoVista Innovative Therapies, Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
OncoVista Innovative Therapies, Inc. Key Executives
OncoVista Innovative Therapies, Inc. Major Shareholders
OncoVista Innovative Therapies, Inc. History
OncoVista Innovative Therapies, Inc. Products
Revenues by Segment
Revenues by Region
OncoVista Innovative Therapies, Inc. Offices and Representations
OncoVista Innovative Therapies, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
OncoVista Innovative Therapies, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
OncoVista Innovative Therapies, Inc. Capital Market Snapshot
OncoVista Innovative Therapies, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
OncoVista Innovative Therapies, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
OncoVista Innovative Therapies, Inc. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

• How to use the strengths to take advantage of the opportunities?
• How to use the strengths to reduce likelihood and impact of the threats?
• How to overcome the weaknesses that obstruct taking advantage of the opportunities?
• How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

• Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
• Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
• Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
• Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
• Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
• Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

1. What composes a threat of substitute products and services?
2. Is there a threat of new competitors entering the market?
3. What is the intensity of competitive rivalry?
4. How big is the bargaining power of buyers?
5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

• Tangible resources
  • Financial
  • Physical
  • Technological
  • Organizational
• Intangible resources
  • Human
  • Innovation and Creativity
  • Reputation
• Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

• Valuable?
• Rare?
• Costly to imitate?
• Organized properly?